Genfit S.A. (GNFT)

Market Cap	221.31M
Revenue (ttm)	73.19M
Net Income (ttm)	1.56M
Shares Out	49.79M
EPS (ttm)	0.03
PE Ratio	141.85
Forward PE	1.82
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,105
Open	4.440
Previous Close	4.315
Day's Range	4.220 - 4.440
52-Week Range	2.550 - 6.423
Beta	1.07
Analysts	Strong Buy
Price Target	13.00 (+196.47%)
Earnings Date	Apr 24, 2025

About GNFT

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patien...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 27, 2019
• Employees: 180
• Stock Exchange: NASDAQ
• Ticker Symbol: GNFT
• Website: https://www.genfit.com

Financial Performance

Financial numbers in EUR

Analyst Forecast

According to one analyst, the rating for GNFT stock is "Strong Buy" and the 12-month stock price forecast is $13.0.

Price Target

$13.0

(196.47% upside)

Analyst Consensus: Strong Buy